Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | CFD | P00746 | 1/20 | 0.39 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.39 |
| ▸ | GLRB | P48167 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 2/20 | 0.38 |
| ▸ | RXRG | P48443 | 2/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2207014 | 0.82 | NR1H4 (0.41) | NR1H4EPHX2GAAGLRA3GLRB | |
| SCHEMBL3661976 | 0.82 | CES2 (0.44) | RXRBRXRARXRGCES2CES1 | |
| SCHEMBL8518617 | 0.82 | FOLH1 (0.51) | GAAMEN1KMT2AMAPK1 | |
| SCHEMBL29601963 | 0.79 | NR1H4 (0.41) | NR1H4EPHX2GAAMEN1KMT2A | |
| SCHEMBL2857663 | 0.79 | KLKB1 (0.48) | MEN1KMT2ACYP4F2CYP4A11CFD | |
| SCHEMBL1069725 | 0.79 | FOLH1 (0.51) | GAAMEN1KMT2ACYP4F2CYP4A11 | |
| SCHEMBL9078912 | 0.78 | GRB2 (0.39) | NR1H4EPHX2GAAMEN1KMT2A | |
| SCHEMBL16823553 | 0.78 | PPARA (0.41) | NR1H4EPHX2GAAMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL5963870 | 0.78 | LMNA (0.43) | NR1H4EPHX2GAAMEN1KMT2A | |
| SCHEMBL27890311 | 0.78 | CYP4F2 (0.40) | NR1H4GAAMEN1KMT2ACYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3455224-B1 | SUBSTITUTED 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-3(2H)-ONES AND 2,5,6,7-TETRAHYDRO-3H-PYRROLO[2,1-C][1,2,4]TRIAZOL-3-ONES, AND USE THEREOF | BAYER AG (DE) | 2024-03-27 | — | — | EP | disclosed |
| EP-3177621-B1 | NOVEL HDAC6 INHIBITORS AND THEIR USES | UNIV REGENSBURG (DE) | 2021-11-10 | — | — | EP | disclosed |
| EP-3455224-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-3(2H)-ONES AND 2,5,6,7-TETRAHYDRO-3H-PYRROLO[2,1-C][1,2,4]TRIAZOL-3-ONES, AND USE THEREOF | Bayer Aktiengesellschaft (DE) | 2019-03-20 | — | — | EP | disclosed |
| US-10106540-B2 | HDAC6 inhibitors and their uses | UNIVERSITÄT REGENSBURG (DE) | 2018-10-23 | — | — | US | disclosed |
| WO-2017194459-A1 | SUBSTITUTED 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-3(2H)-ONES AND 2,5,6,7-TETRAHYDRO-3H-PYRROLO[2,1-C][1,2,4]TRIAZOL-3-ONES, AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2017-11-16 | — | — | WO | disclosed |
| US-20170210743-A1 | NOVEL HDAC6 INHIBITORS AND THEIR USES | Universitätsklinikum Jena (DE) | 2017-07-27 | — | — | US | disclosed |
| EP-3083594-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES AS ADRENORECEPTOR ALPHA 2C ANTAGONISTS | Bayer Pharma Aktiengesellschaft (DE) | 2016-10-26 | — | — | EP | disclosed |
| EP-2621508-B1 | N-CARBOXYALKYL AURISTATINS AND THE USE THEREOF | SEATTLE GENETICS INC (US) | 2015-08-26 | — | — | EP | disclosed |
| WO-2015091415-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES AS ADRENORECEPTOR ALPHA 2C ANTAGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
| US-20150148298-A1 | N-CARBOXYALKYL-AURISTATIN AND USE THEREOF | SEATTLE GENETICS, INC. (US) | 2015-05-28 | — | — | US | disclosed |
| US-20030130278-A1 | Alkynylated fused ring pyrimidine compounds | GAUDILLIERE BERNARD (FR) | 2003-07-10 | — | — | US | disclosed |
| US-6583126-B2 | Treating diabetes, obesity, and diabetes-related diseases. | MERCK EROSST CANADA & CO. | 2003-06-24 | — | — | US | disclosed |
| WO-2003033478-A1 | ALKYNYLATED FUSED RING PYRIMIDINE COMPOUNDS AS MATRIX METALLOPROTEASE-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2003-04-24 | — | — | WO | disclosed |
| WO-2003033477-A1 | ALKYNLATED FUSED RING PYRIMIDINE COMPOUNDS AS MATRIX METALLOPROTEASE-13 INHIBITOR | WARNER-LAMBERT COMPANY LLC (US) | 2003-04-24 | — | — | WO | disclosed |
| US-20030078276-A1 | Matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2003-04-24 | — | — | US | disclosed |
| US-20020156069-A1 | Benzo thiadiazine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY | 2002-10-24 | — | — | US | disclosed |
| EP-1242432-A1 | PHOSPHONIC ACID DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) | MERCK FROSST CANADA INC. (CA) | 2002-09-25 | — | — | EP | disclosed |
| WO-2002064578-A1 | BENZO THIADIAZINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| US-20020052344-A1 | Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase IB (PTP-IB) | MERCK FROSST CANADA LTD. (CA) | 2002-05-02 | — | — | US | disclosed |
| WO-2001046205-A1 | PHOSPHONIC ACID DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) | MERCK FROSST CANADA & CO. (CA) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052344-A1 | Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase IB (PTP-IB) | PTPRO, PTPRC, PPM1B | NR1H4 2405/4885EPHX2 2077/4885GAA 158/4885 |
| US-20020156069-A1 | Benzo thiadiazine matrix metalloproteinase inhibitors | MMP15, MMP13, MMP3 | NR1H4 1233/4885EPHX2 1983/4885GAA 3169/4885 |
| US-20030078276-A1 | Matrix metalloproteinase inhibitors | MMP13, MMP25, MMP12 | NR1H4 2392/4885EPHX2 4127/4885GAA 2138/4885 |
| US-20030130278-A1 | Alkynylated fused ring pyrimidine compounds | MMP13, TIMP3, MMP3 | NR1H4 1683/4885EPHX2 869/4885GAA 948/4885 |
| US-20150148298-A1 | N-CARBOXYALKYL-AURISTATIN AND USE THEREOF | HDGF, HGFAC, HGF | NR1H4 1849/4885EPHX2 2630/4885GAA 1530/4885 |
| US-20170210743-A1 | NOVEL HDAC6 INHIBITORS AND THEIR USES | HDAC6, HDAC5, HDAC4 | NR1H4 517/4885EPHX2 2788/4885GAA 113/4885 |
| US-10106540-B2 | HDAC6 inhibitors and their uses | HDAC6, HDAC5, HDAC4 | NR1H4 506/4885EPHX2 3026/4885GAA 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.